Select Your Region
Global
A study of a medicine (GDC-0919) combined with another medicine (atezolizumab) in patients with cancer that has grown or spread
A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors
Cancer Solid Tumors
Basic Details
All
≥18 Years
No
Sponsor
Genentech, Inc.
Phase
Phase 1
Study Identifier
NCT02471846, GO29779, 2015-001741-88
Researchers wanted to find out what dose of the study medicine (GDC-0919) was safe to combine with another medicine (atezolizumab). Both of these medicines have an effect on the immune system of the patient. The combination treatment was given to cancer patients to find out what effects, good and/or bad, GDC-0919 and atezolizumab had on patients and on their cancers. All patients received the same dose of atezolizumab; GDC-0919 was given at different doses to different groups of patients.
The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.
The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.
Results Disclaimer
What you can do next
To find this study again later, copy and save the study number:
{{ctId}}
To see if this study is a good fit, talk to your doctor or nurse you trust.
Together, you can look at the For Medical Professional tab and look into your medical history.
Some medical centers in this study offer a contact line. Click "Find participating medical centers" in the map below.
For the latest version of this information please go to www.forpatients.roche.com